248 related articles for article (PubMed ID: 25586788)
1. EZH2 expression is a prognostic factor in childhood intracranial ependymoma: a Canadian Pediatric Brain Tumor Consortium study.
Li AM; Dunham C; Tabori U; Carret AS; McNeely PD; Johnston D; Lafay-Cousin L; Wilson B; Eisenstat DD; Jabado N; Zelcer S; Silva M; Scheinemann K; Fryer C; Hendson G; Fotovati A; Hawkins C; Yip S; Dunn SE; Hukin J
Cancer; 2015 May; 121(9):1499-507. PubMed ID: 25586788
[TBL] [Abstract][Full Text] [Related]
2. The role of resection alone in select children with intracranial ependymoma: the Canadian Pediatric Brain Tumour Consortium experience.
Ailon T; Dunham C; Carret AS; Tabori U; Mcneely PD; Zelcer S; Wilson B; Lafay-Cousin L; Johnston D; Eisenstat DD; Silva M; Jabado N; Goddard KJ; Fryer C; Hendson G; Hawkins C; Dunn S; Yip S; Singhal A; Hukin J
Childs Nerv Syst; 2015 Jan; 31(1):57-65. PubMed ID: 25391979
[TBL] [Abstract][Full Text] [Related]
3. PI3K pathway activation provides a novel therapeutic target for pediatric ependymoma and is an independent marker of progression-free survival.
Rogers HA; Mayne C; Chapman RJ; Kilday JP; Coyle B; Grundy RG
Clin Cancer Res; 2013 Dec; 19(23):6450-60. PubMed ID: 24077346
[TBL] [Abstract][Full Text] [Related]
4. Combined aberrant expression of Bmi1 and EZH2 is predictive of poor prognosis in glioma patients.
Wu Z; Wang Q; Wang L; Li G; Liu H; Fan F; Li Z; Li Y; Tu Y
J Neurol Sci; 2013 Dec; 335(1-2):191-6. PubMed ID: 24139839
[TBL] [Abstract][Full Text] [Related]
5. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
[TBL] [Abstract][Full Text] [Related]
6. Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma.
Ridley L; Rahman R; Brundler MA; Ellison D; Lowe J; Robson K; Prebble E; Luckett I; Gilbertson RJ; Parkes S; Rand V; Coyle B; Grundy RG;
Neuro Oncol; 2008 Oct; 10(5):675-89. PubMed ID: 18701711
[TBL] [Abstract][Full Text] [Related]
7. Altered MicroRNA Expression Is Associated with Tumor Grade, Molecular Background and Outcome in Childhood Infratentorial Ependymoma.
Zakrzewska M; Fendler W; Zakrzewski K; Sikorska B; Grajkowska W; Dembowska-Bagińska B; Filipek I; Stefańczyk Ł; Liberski PP
PLoS One; 2016; 11(7):e0158464. PubMed ID: 27390862
[TBL] [Abstract][Full Text] [Related]
8. EZH2 is a negative prognostic factor and exhibits pro-oncogenic activity in glioblastoma.
Zhang J; Chen L; Han L; Shi Z; Zhang J; Pu P; Kang C
Cancer Lett; 2015 Jan; 356(2 Pt B):929-36. PubMed ID: 25444902
[TBL] [Abstract][Full Text] [Related]
9. Co-expression of Bmi1 and EZH2 as an independent poor prognostic factor in esophageal squamous cell carcinoma.
Ha SY; Kim SH
Pathol Res Pract; 2012 Aug; 208(8):462-9. PubMed ID: 22766604
[TBL] [Abstract][Full Text] [Related]
10. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer.
Huqun ; Ishikawa R; Zhang J; Miyazawa H; Goto Y; Shimizu Y; Hagiwara K; Koyama N
Cancer; 2012 Mar; 118(6):1599-606. PubMed ID: 21837672
[TBL] [Abstract][Full Text] [Related]
11. EZHIP/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma.
Hübner JM; Müller T; Papageorgiou DN; Mauermann M; Krijgsveld J; Russell RB; Ellison DW; Pfister SM; Pajtler KW; Kool M
Neuro Oncol; 2019 Jul; 21(7):878-889. PubMed ID: 30923826
[TBL] [Abstract][Full Text] [Related]
12. High expression of Polycomb group protein EZH2 predicts poor survival in salivary gland adenoid cystic carcinoma.
Vékony H; Raaphorst FM; Otte AP; van Lohuizen M; Leemans CR; van der Waal I; Bloemena E
J Clin Pathol; 2008 Jun; 61(6):744-9. PubMed ID: 18326020
[TBL] [Abstract][Full Text] [Related]
13. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance.
Kikuchi J; Kinoshita I; Shimizu Y; Kikuchi E; Konishi J; Oizumi S; Kaga K; Matsuno Y; Nishimura M; Dosaka-Akita H
Cancer; 2010 Jun; 116(12):3015-24. PubMed ID: 20564407
[TBL] [Abstract][Full Text] [Related]
14. Enhancer of zeste homolog 2 expression is associated with metastasis and adverse clinical outcome in clear cell renal cell carcinoma: a comparative study and review of the literature.
Xu B; Abourbih S; Sircar K; Kassouf W; Mansure JJ; Aprikian A; Tanguay S; Brimo F
Arch Pathol Lab Med; 2013 Oct; 137(10):1326-36. PubMed ID: 24079759
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-144 suppresses tumorigenesis and tumor progression of astrocytoma by targeting EZH2.
Lin L; Zheng Y; Tu Y; Wang Z; Liu H; Lu X; Xu L; Yuan J
Hum Pathol; 2015 Jul; 46(7):971-80. PubMed ID: 25907866
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical analysis of polycomb group protein expression in advanced gastric cancer.
Lee H; Yoon SO; Jeong WY; Kim HK; Kim A; Kim BH
Hum Pathol; 2012 Oct; 43(10):1704-10. PubMed ID: 22520951
[TBL] [Abstract][Full Text] [Related]
17. EZH2 expression in gliomas: Correlation with CDKN2A gene deletion/ p16 loss and MIB-1 proliferation index.
Purkait S; Sharma V; Jha P; Sharma MC; Suri V; Suri A; Sharma BS; Sarkar C
Neuropathology; 2015 Oct; 35(5):421-31. PubMed ID: 26096306
[TBL] [Abstract][Full Text] [Related]
18. EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma.
Behrens C; Solis LM; Lin H; Yuan P; Tang X; Kadara H; Riquelme E; Galindo H; Moran CA; Kalhor N; Swisher SG; Simon GR; Stewart DJ; Lee JJ; Wistuba II
Clin Cancer Res; 2013 Dec; 19(23):6556-65. PubMed ID: 24097870
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of EZH2 and loss of expression of PTEN is associated with invasion, metastasis, and poor progression of gallbladder adenocarcinoma.
Liu DC; Yang ZL
Pathol Res Pract; 2011 Aug; 207(8):472-8. PubMed ID: 21719208
[TBL] [Abstract][Full Text] [Related]
20. Malignant rhabdoid tumors express stem cell factors, which relate to the expression of EZH2 and Id proteins.
Venneti S; Le P; Martinez D; Xie SX; Sullivan LM; Rorke-Adams LB; Pawel B; Judkins AR
Am J Surg Pathol; 2011 Oct; 35(10):1463-72. PubMed ID: 21921784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
